Novo Nordisk’s Balancing Act: Weighing a Lost CVS Advantage Against a Make-or-Break Data Readout
CVS Caremark revokes Wegovy’s preferred status on formulary, opening door for Eli Lilly. Novo Nordisk shares fall 40%…
Browsing Tag